- Home
- GES vs GYRE Comparison
GES vs GYRE Comparison
Compare GES & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GES
- GYRE
- Stock Information
- Founded
- GES 1981
- GYRE 2002
- Country
- GES Switzerland
- GYRE United States
- Employees
- GES N/A
- GYRE N/A
- Industry
- GES Apparel
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- GES Consumer Discretionary
- GYRE Health Care
- Exchange
- GES Nasdaq
- GYRE Nasdaq
- Market Cap
- GES 879.0M
- GYRE 897.1M
- IPO Year
- GES 1996
- GYRE N/A
- Fundamental
- Price
- GES $16.69
- GYRE $8.20
- Analyst Decision
- GES Buy
- GYRE Strong Buy
- Analyst Count
- GES 5
- GYRE 1
- Target Price
- GES $19.25
- GYRE $18.00
- AVG Volume (30 Days)
- GES 1.6M
- GYRE 96.4K
- Earning Date
- GES 08-27-2025
- GYRE 08-11-2025
- Dividend Yield
- GES 5.37%
- GYRE N/A
- EPS Growth
- GES N/A
- GYRE N/A
- EPS
- GES 0.35
- GYRE 0.02
- Revenue
- GES $3,091,508,000.00
- GYRE $102,189,000.00
- Revenue This Year
- GES $7.67
- GYRE $21.04
- Revenue Next Year
- GES $3.32
- GYRE $89.64
- P/E Ratio
- GES $48.30
- GYRE $177.73
- Revenue Growth
- GES 7.84
- GYRE N/A
- 52 Week Low
- GES $8.48
- GYRE $6.11
- 52 Week High
- GES $20.33
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- GES 67.57
- GYRE 53.35
- Support Level
- GES $16.64
- GYRE $7.55
- Resistance Level
- GES $16.76
- GYRE $8.56
- Average True Range (ATR)
- GES 0.08
- GYRE 0.51
- MACD
- GES -0.11
- GYRE 0.01
- Stochastic Oscillator
- GES 14.52
- GYRE 66.36
About GES Guess? Inc.
Guess? Inc designs, markets distributes, and licenses contemporary apparel and accessories that reflect European fashion sensibilities and American Lifestyle under brands including Guess, Marciano, and G by Guess. The company has five reportable segments: Americas Retail, Americas Wholesale, Europe, Asia, and licensing. Geographically, the company derives maximum revenue from the United States.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.